Description

Rifamycin, 3-[(E)-[[4-[[1-[(3R)-1-(3-carboxy-1-cyclopropyl-7-fluoro-9-methyl-4-oxo-4H-quinolizin-8-yl)-3-pyrrolidinyl]cyclopropyl]methylamino]-1-piperidinyl]imino]methyl]- is a sophisticated, semi-synthetic derivative of the rifamycin class, designed for advanced pharmaceutical research and development. This compound is valued for its potential as a key intermediate or active pharmaceutical ingredient (API) in the creation of next-generation antimicrobial agents. It is primarily targeted at pharmaceutical manufacturers and biotechnology research organizations engaged in the discovery of novel antibiotics to combat resistant bacterial strains.

Application

• Pharmaceutical Intermediate: Serves as a critical building block in the synthesis of novel rifamycin-based antibiotics targeting Gram-positive and mycobacterial infections.
• Antimicrobial Research: Used in preclinical and discovery-phase research to study structure-activity relationships (SAR) and develop new therapeutic entities with improved efficacy.
• API Development: Acts as a potential Active Pharmaceutical Ingredient (API) for formulation into injectable or oral dosage forms after necessary development and regulatory approval.
• Biochemical Research: Employed as a tool compound in microbiological and biochemical assays to investigate bacterial RNA polymerase inhibition mechanisms.
• Reference Standard: Can be supplied as a high-purity analytical reference standard for quality control and method development in analytical laboratories.

Basic Information

Product Name	Rifamycin, 3-[(E)-[[4-[[1-[(3R)-1-(3-carboxy-1-cyclopropyl-7-fluoro-9-methyl-4-oxo-4H-quinolizin-8-yl)-3-pyrrolidinyl]cyclopropyl]methylamino]-1-piperidinyl]imino]methyl]-
CAS No.	922717-97-3
Molecular Formula	Contact for details
Molecular Weight	Contact for details
Synonyms	Rifamycin Derivative 922717-97-3; 3-[(E)-[[4-[[1-[(3R)-1-(3-Carboxy-1-cyclopropyl-7-fluoro-9-methyl-4-oxo-4H-quinolizin-8-yl)-3-pyrrolidinyl]cyclopropyl]methylamino]-1-piperidinyl]imino]methyl]rifamycin; Rifamycin SV derivative; Advanced Rifamycin Analog; Antibacterial Research Compound; Quinolizine-rifamycin Hybrid; RNA Polymerase Inhibitor Intermediate
EINECS	Contact for details

Quality Control

Our rifamycin derivative is produced under strict quality management systems to ensure batch-to-batch consistency and high purity suitable for research and development purposes. All materials are accompanied by a comprehensive Certificate of Analysis (COA) detailing identity, purity, and impurity profiles. We support compliance with cGMP guidelines for advanced intermediates and can provide documentation to meet the stringent requirements of pharmaceutical development partners.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at controlled room temperature (15-25°C). The product is light-sensitive and should be handled under appropriate conditions to maintain stability.

Specification

Item	Specification
Appearance	Yellow to Orange Powder
Identification (HPLC)	Conforms to Reference Standard
Identification (IR)	Conforms to Structure
Assay (HPLC)	≥ 95.0%
Related Substances (HPLC)	Total Impurities ≤ 5.0%
Residual Solvents (GC)	Complies with ICH Guidelines
Water Content (KF)	≤ 1.0%

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.